Boston, MA 03/13/2014 (wallstreetpr) – Kratos Defense & Security Solutions, Inc (NASDAQ:KTOS) was hurting in yesterday’s trading after the company reported decline in revenue in the fourth quarter on both products and services. Yet loss in the quarter narrowed slightly. Shares were last seen at $7.56, down 5.26 percent Wednesday. The day was high on volume trading that exceeded daily average. Investors traded the share within the intraday price range of $7.05 low and $7.81 high. The specialized security technology provider said its revenue declined 11 percent to $235.7 million in the fourth quarter, thus missing the target at $251.7 million that analysts estimated. The loss narrowed to 13 cents from $1.59 in the corresponding quarter a year earlier.
Galectin Therapeutics Inc. (NASDAQ:GALT) has entered a collaborative arrangement with SBH Sciences Inc to establish a joint venture. SBH is provider of growth factors, cytokines and biologics. In collaboration with GALT, the two companies have established Galectin Sciences LLC which will be concerned with research and development of organic molecule inhibitors. Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) were last seen at $15.95, down 1.3 percent Wednesday. It was a day when nearly half the normal daily average share volume changed hands between the low and high intraday prices of $15.52 and $16.35.
LDR Holding Corp (NASDAQ:LDRH) has announced an important technology approval that would enhance the efficacy of its devices, more so in the cervical disc replacement. The company’s CEO and President Christophe Lavigne has praised the approval and termed it a milestone for the company and its clients. LDRH is concerned with designing and commercializing medical devices, especially those focused on addressing spine disorders. Shares of LDR Holding Corp (NASDAQ:LDRH) were up 5.68 percent to $39.44 in the last session. A fairly large volume of shares was traded in the Wednesday session were the intraday prices ranged at the low and high boundaries of $33.38 and $40 respectively. The $923.92 million market capped company recently had its 12-moonth price target boosted to $33 from $27 by analysts at Piper Jaffray.
